Imunon, Inc. · NASDAQ:IMNN

Imunon — 3rd International Vaccine Congress 2023

27 slides from Imunon's conference presentation, Oct 23, 2023

  1. Slide 1: A DNA-based Vaccine Technology Independent of Virus or Device

    A DNA-based Vaccine Technology Independent of Virus or Device Khursheed Anwer Ph.D.,MBA Executive Vice President & CSO 3rd International Vaccine Congress October 23-25, 2023 Boston, MA © 2022 IMUNON Inc. PAGE 1

  2. Slide 2: DNA Vaccines: Well-Suited to Overcome the Limitations of Current Vaccines

    DNA Vaccines: Well-Suited to Overcome the Limitations of Current Vaccines Current Vaccines & Limitations mRNA • Short duration of immune responses • Poor stability at working temperatures Protein • Challenges in manufacturing & subunit mixtures • Poor cytotoxic T-cell responses DNA Vaccine Advantage

  3. Slide 3: PLACCINE – A Novel DNA Vaccine Technology

    PLACCINE – A Novel DNA Vaccine Technology Relies on Synthetic Delivery Systems Non-viral Non-device Non-LNP Covalently - Functionalized amphiphilic polymer delivery systems • Dispersion • Gene Expression X X Formulated DNA • Protection • Membrane Interaction • Immunogenicity Backbone • Adjuvant X- f

  4. Slide 4: DNA Protection & Enhanced Gene Expression by PLACCINE Delivery System

    DNA Protection & Enhanced Gene Expression by PLACCINE Delivery System Protection of DNA Degradation Gene Expression: 10-15 fold > Naked DNA Non-functionalized Functionalized 24 hours 7 days Luciferase (RLU/mg protein) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Degraded DNA Protected DNA 21-025 Naked DNA Lot#1

  5. Slide 5: PlaCCine Addresses the Limitations of Current Vaccines

    PlaCCine Addresses the Limitations of Current Vaccines © 2022 IMUNON Inc. PAGE 5

  6. Slide 6: More Durable Antigen Expression Compared to mRNA Vaccines

    More Durable Antigen Expression Compared to mRNA Vaccines PBS mRNA-LNP PlaCCine Luciferase Expression ~100%- fold 1 3 6 17 24 30 37 43 Days Durable antigen expression- a potential solution to short-lived mRNA vaccines © 2022 IMUNON Inc. PAGE 6

  7. Slide 7: More Durable Immune Response Compared to mRNA Vaccines

    More Durable Immune Response Compared to mRNA Vaccines Prime and Day 14 boost T-cell Response (IFN-g) PBS pVac-15 pVac-16 mRNA PBS pVac-15 pVac-16 mRNA PlaCCine Vaccines Durable gene expression potentially translated into durable immune response © 2022 IMUNON Inc. PAGE 7

  8. Slide 8: Rising Immune Response Kinetic Compared to mRNA Vaccines at a Single Dose

    Rising Immune Response Kinetic Compared to mRNA Vaccines at a Single Dose Rising response Higher T-cell response over time at final timepoint No increase over time PBS mRNA PlaCCine PBS mRNA PlaCCine Favorable PlaCCine kinetics is suitable for single dose vaccination © 2022 IMUNON Inc. PAGE 8

  9. Slide 9: Comparable Immune Responses to a Comparator DNA Vaccine

    Comparable Immune Responses to a Comparator DNA Vaccine PlaCCine Offers Better Commercial Viability by Compliance Day 21 PlaCCine 10 mg Day 35 PlaCCine 10 mg (pre-boost) Comparator 10 mg (post-boost) Comparator 10 mg (Geometric mean. 99% CI) Ab Titer Day 35 CD4 CD8 (Geometric mean. 99% CI) PlaCCine

  10. Slide 10: Better T Cell Responses Compared to Viral Vector DNA & Protein Vaccines

    Better T Cell Responses Compared to Viral Vector DNA & Protein Vaccines PlaCCine Offers Better Commercial Viability due to Safety Advantage 106 PBS T-cell Response nAb Response PlaCCine 1500 Day 35- two doses Day 35- two doses Adenovirus 105 Protein SFC/106 Cells Endpoint Titer 1000 104 500 103 102

  11. Slide 11: Manufacturing Flexibility Compared to mRNA & Protein Vaccines

    Manufacturing Flexibility Compared to mRNA & Protein Vaccines Plug & Play - Rapid Production of Vaccines C AA TTG CAG Antigen Coding Cassettes SARS-CoV2 Variants Multiple antigens are targeted in a single plasmid lot versus a mixture of multiple mRNA or protein lots- Cost & speed advantage with PlaC

  12. Slide 12: Stable at 4°C for at Least 12 Months

    Stable at 4o C for at Least 12 Months PlaCCine- Commercial Advantage Over mRNA Vaccines IgG Response • Vector: pVac-17 (D614G-Delta) 1m • Formulation: PlaCCine 3m 6m 10 5 9m 12m 10 4 Endpoint Titer 10 3 10 2 4⁰C Storage 10 1 1 3 6 9 12 Months 10 0 4C 4C 4C 4C 4C h h h h h es es es es es Fr Fr Fr Fr

  13. Slide 13: Stable at 37°C for at least 14 Days

    Stable at 37o C for at least 14 Days PlaCCine - Commercial Advantage over mRNA Vaccines NS = 0.141 NS = 0.06 Day-7 Day-14 4o C 37o C 4o C 37o C 4o C 37o C 4o C 37o C © 2022 IMUNON Inc. PAGE 13

  14. Slide 14: IMNN-101 COVID-Vaccine

    IMNN-101 C O V I D - 1 9 Va c c i n e © 2022 IMUNON Inc. PAGE 14

  15. Slide 15: IMNN-101 Development Status

    IMNN-001: Development Status IMNN-101 Development Timelines *XBB1.5 Variant PlaCCine delivery system Spike DNA Preclinical Proof of Concept IND-Enabling Studies Safety Tox (ongoing) 4Q 2023 Vaccine Plasmid Delivery System Biodistribution (ongoing) 4Q 2023 Clinical Lot 1Q 2024 * Current Vaccine Varia

  16. Slide 16: Robust IgG & T-cell Responses in a Mouse Model

    Robust IgG & T-cell Responses in a Mouse Model Prime & Boost 105 IgG 5 nAbs 2000 T-cells 4 1500 104 Log IC50 Titer 3 Endpoint Titer 1000 SC/106 Cells 103 2 500 102 1 PBS 50 mg 100 mg PBS 50 mg 100 mg PBS IMNN-101 IMNN-101 IMNN-101 © 2022 IMUNON Inc. PAGE 16

  17. Slide 17: CD8 and CD4 T-cell Responses in a Mouse Model

    CD8 and CD4 T-cell Responses in a Mouse Model Prime & Boost CD4 CD4 T cells (%) TNF-a IFN-g IL-12 pVac-76 (mg) 50 100 CD8 CD8 T cells (%) pVac-76 (mg) 50 100 © 2022 IMUNON Inc. PAGE 17

  18. Slide 18: Over 90% Protection From Viral Challenge in Mice

    Over 90% Protection From Viral Challenge in Mice Prototype Vaccines - Early SARS-CoV-2 Variants TCID50 Tissue Culture Infection Dose D614G Challenge ( 2.5 x 105) ) Delta Challenge (7 x 104) TCID50/gm of lung TCID50/gm of lung LOD LOD Placebo pVac15 pVac17 Placebo pVac16 pVac17 IMNN-101 Prototype Vac

  19. Slide 19: Comparable Protection to mRNA Vaccine in Monkeys

    Comparable Protection to mRNA Vaccine in Monkeys Prototype Vaccines - Early SARS-CoV-2 Variants Bronchoalveolar Lavage IMNN-101 Prototype Vaccines 2 Days after Challenge 4 Days after Challenge 7 Days after Challenge Placebo Log Copies/ml pVac-15 (1, 1 mg) pVac-16 (2, 2 mg) pVac-15 (5, 1 mg) mRNA mRN

  20. Slide 20: IMNN-101: Single Dose, Placebo Controlled Phase 1/2 Trial in Healthy Subjects

    IMNN-101: Single Dose, Placebo Controlled Phase 1/2 Trial in Healthy Subjects Projected Start Date - Q1-2024 Rapid Dose Escalation- Expanded Phase 2 for Speedy Completion DNA Dose Escalation (mg) 0.5 1.0 2.0 Placebo (n = 8 each) Vaccine -30 Days Day-1 Day-7 Day-28 Day-90 Day-180 Day-365 Prescreening

  21. Slide 21: PlaCCine Vaccines

    PlaCCine Vaccines Additional Pathogens • Flu • LASSA • Marburg • Monkeypox Active Vaccine Partnerships NIAID/NIH – LASSA Wistar Institute – Flu, Marburg © 2022 IMUNON Inc. PAGE 21

  22. Slide 22: PlaCCine Vaccines - Immunogenicity Against Additional Pathogens

    PlaCCine Vaccines - Immunogenicity Against Additional Pathogens Marburg (Wistar Institute) Influenza (Wistar Institute) Lassa (NIH/NIAID) IgG IgG T-cell IFN-g MARV GP-binding 1500 IgG Titers c e l ls 6 1000 S F C /1 0 500 0 PBS pVac-68 pVac-69 pVac-70 *p <0.05 **p <0.01 T-cell T-cell ****p<0.001 T-c

  23. Slide 23: Cancer Vaccine Modalities

    Cancer Vaccine Modalities © 2022 IMUNON Inc. PAGE 23

  24. Slide 24: Imunon's Immuno-Oncology & Cancer Vaccine Portfolio

    Imunon’s Immuno-Oncology & Cancer Vaccine Portfolio Three Technology Platforms TheraPlas FixPlas IndiPlas Immune Modulation by Tumor-Associated Antigen Neoantigens Cytokine Therapy Vaccines (personalized vaccines) IMNN-001 IMNN-201 IMNN-001 Normal Cell Tumor Cell Self antigens Tumor-associated Tumor

  25. Slide 25: FixPlas Reduces Tumor Growth and Improved Survival in Mouse Melanoma

    FixPlas Reduces Tumor Growth and Improved Survival in Mouse Melanoma pVAC-Trp2 SV40 bGH mTrp2 CI CMV Enhancer KanR Monitored for tumor growth & mortality pVAC-NYESO-1 SV40 bGH hNYESO-1 CI CMV Enhancer KanR Tumor volume (mm3) Percent Survival Tumor volume (mm3) © 2022 IMUNON Inc. PAGE 25

  26. Slide 26: FixPlas Produces Cellular Responses in Mouse Melanoma

    FixPlas Produces Cellular Responses in Mouse Melanoma ELISpot Demonstrates Induction of a Strong Cellular Response to NY-ESO SFC/106 cells Flow Cytometry Demonstrates the Cellular Immune Response is Predominantly CD4 5 NYESO Stimulation TNFa IFNy 4 CD8+ Tcells (%) CD4+ Tcells (%) 3 2 1 0 Control TRP

  27. Slide 27: PLACCINE - A New Class of Prophylactic Vaccines

    PLACCINE - A New Class of Prophylactic Vaccines • PLACCINE leverages the DNA advantages to achieve: • Durable humoral and cytotoxic immune responses • Single multivalent vaccines for better breadth of immune response • Stability at working temperatures • Flexible manufacturing • Independence from vi

Imunon — 3rd International Vaccine Congress 2023 on 6ix